Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria

Circulation

Volumn 112, Issue 10, 2005, Pages 1435-1443

  Quinkler, Marcus ^a,c   Zehnder, Daniel ^b   Eardley, Kevin S ^d   Lepenies, Julia ^b   Howie, Alexander J ^a   Hughes, Susan V ^a   Cockwell, Paul ^b   Hewison, Martin ^a   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d NONE

Author keywords

Blood pressure; Hormones; Hypertension, renal; Kidney; Receptors

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CD34 ANTIGEN; CD68 ANTIGEN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; INTERLEUKIN 6; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; THIAZIDE DIURETIC AGENT; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; FEMALE; HEART FAILURE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INJURY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROSCLEROSIS; PRIORITY JOURNAL; PROTEINURIA; RENOVASCULAR HYPERTENSION; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE; BIOPSY; BLOOD PRESSURE; CHEMOKINE CCL2; FEMALE; GLOMERULAR BASEMENT MEMBRANE; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERLEUKIN-6; ISCHEMIA; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; PROTEINURIA; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 24744454626     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.539122     Document Type: Article

References (53)

1. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993-2000.
2. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial: Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN): Ramipril Efficacy in Nephropathy. Lancet. 1998;352:1252-1256.
3. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1992;90:766-771.
4. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063-1068.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiolensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
6. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
8. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
9. Horiuchi M, Nishiyama H, Hama J, Takenaka T, Kondo H, Kino H, Nagata S, Sugimura K, Katori R. Characterization of renal aldosterone receptors in genetically hypertensive rats. Am J Physiol. 1993;264(pt 2):F286-F291.
10. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31(pt 2):451-458.
11. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999;33(pt 2):232-237.
12. Delcayre C, Silvestre JS, Garnier A, Oubenaissa A, Cailmail S, Tatara E, Swynghedauw B, Robert V. Cardiac aldosterone production and ventricular remodeling. Kidney Int. 2000;57:1346-1351.
13. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-3878.
14. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791-1800.
15. Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392: 565-568.
16. Wang Y, Rangan GK, Tay YC, Wang Y, Harris DC. Induction of monocyte chemoattractant protein-1 by albumin is mediated by nuclear factor κB in proximal tubule cells. J Am Soc Nephrol. 1999;10: 1204-1213.
17. Tang S, Leung JC, Abe K, Chan KW, Chan LY, Chan TM, Lai KN. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest. 2003;111:515-527.
18. Hene RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982;21:98-101.
19. Berl T, Katz FH, Henrich WL, de Torrente A, Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int. 1978;14:228-235.
20. Conn JW, Knopf RF. Clinical characteristics of primary aldosteronism from analysis of 145 cases. Am J Surg. 1964;107:159-172.
21. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001;345:925-926.
22. Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant. 2003;18:1984-1992.
23. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41: 64-68.
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
25. Bujalska IJ, Walker EA, Tomlinson JW, Hewison M, Stewart PM. 11β-Hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr Res. 2002;28:449-461.
26. Howie AJ, Ferreira MA, Adu D. Prognostic value of simple measurement of chronic damage in renal biopsy specimens. Nephrol Dial Transplant. 2001;16:1163-1169.
27. Thomas ME, Harris KP, Walls J, Furness PN, Brunskill NJ. Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria. Am J Physiol Renal Physiol. 2002;283:F640-F647.
28. Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C. Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int. 1999;55:1878-1884.
29. Gerling IC, Sun Y, Ahokas RA, Wodi LA, Bhattacharya SK, Warrington KJ, Postlethwaite AE, Weber KT. Aldosteronism; an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol. 2003;285:H813-H821.
30. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578-2583.
31. Ota T, Tamura M, Osajima A, Doi Y, Kudo H, Anai H, Miyazaki M, Nishino T, Nakashima Y. Expression of monocyte chemoattractant protein-1 in proximal tubular epithelial cells in a rat model of progressive kidney failure. J Lab Clin Med. 2002;140:43-51.
32. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Montinaro V, Marra F, Schena FP. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol. 1996;7:906-913.
33. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda SI, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima K, Yokoyama H. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000;58:1492-1499.
34. Reams GP, Bauer JH. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med. 1986;146:2145-2148.
35. Cameron JS. Proteinuria and progression in human glomerular diseases. Am J Nephrol. 1990;10(suppl 1):81-87.
36. Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int. 1995;47:1546-1557.
37. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation. Kidney Int. 1998; 53:1608-1615.
38. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66:1-9.
39. Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring PA, Lu L, Bhattacharya SK, Postlethwaite AE, Weber KT. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res. 2003;93:el24-el35.
40. 2 in peripheral blood mononuclear cells. Circulation. 2005;111: 51-57.
41. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, Nehme J, Ambroisine ML, De Angelis N, Morineau G, d'Estienne P, Fischmeister R, Heymes C, Pinet F, Delcayre C. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation. 2004;110:1819-1825.
42. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32: 107-114.
43. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-658.
44. Coletta I, Soldo L, Polentarutti N, Mancini F, Guglielmotti A, Pinza M, Mantovani A, Milanese C. Selective induction of MCP-1 in human mesangial cells by the IL-6/SIL-6R complex. Exp Nephrol. 2000;8: 37-43.
45. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-β1 in renal fibrosis of rats. Hypertension. 2000; 35:1078-1084.
46. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int. 2004;66:1493-1502.
47. Juknevicius I, Segal V, Kren S, Lee R, Hosteller TH. Effect of aldosterone on renal transforming growth factor-β. Am J Physiol Renal Physiol. 2004;286:F1059-F1062.
48. Shankland SJ, Scholey JW, Ly H, Thai K. Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int. 1994;46: 430-442.
49. Pfeiffer A, Middelberg-Bisping K, Drewes C, Schatz H. Elevated plasma levels of transforming growth factor-β1 in NIDDM. Diabetes Care. 1996;19:1113-1117.
50. Goumenos DS, Tsakas S, El Nahas AM, Alexandn S, Oldroyd S, Kalliakmani P, Vlachojannis JG. Transforming growth factor-β(1) in lhe kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant. 2002;17:2145-2152.
51. McLaughlin N, Gehr TW, Sica DA. Aldosterone-receplor antagonism and end-stage renal disease. Curr Hypertens Rep. 2004;6:327-330.
52. Barnes BJ, Howard PA. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Ann Pharmacother. 2005;39: 68-76.
53. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab. 2004;89: 2736-2740.